A meta-analysis of 15 different randomized, placebo-controlled trials of 4,495 subjects revealed a 1.57-fold (95% CI 1.19–2.08) increase in the risk of sexual dysfunction as compared to placebo in both patients receiving 5 AR inhibitors for BPH and androgenic alopecia (AGA) [25]. Here, AR is linked to benign prostatic hyperplasia.